Troy Edward Wilson, President and CEO of Kura Oncology, Inc. (NASDAQ:KURA), filed a Form 4 on August 17, 2026, disclosing the open-market purchase of 100,000 shares of common stock at a weighted average price of $11.12 per share.

Key Highlights

  • Purchase transaction: Wilson acquired 100,000 shares of Kura Oncology common stock on August 17, 2026, using transaction code "P" (open-market purchase).
  • Weighted average price: The reported price of $11.12 per share reflects a weighted average across multiple trades ranging from $10.87 to $11.31, according to the filing.
  • Indirect ownership after transaction: Following the purchase, Wilson beneficially owns 379,194 shares indirectly through the One Fish Two Fish Revocable Trust.
  • Additional indirect holdings: The filing also reports 300,000 shares held indirectly through the Lorax Charitable Remainder Unitrust.
  • Direct holdings: The filing lists 435,456 shares held directly by Wilson.
  • Reporting person roles: Wilson is identified as both a Director and an Officer (President and CEO) of Kura Oncology, Inc.

Details of Troy Wilson's Common Stock Purchase and Beneficial Ownership at Kura Oncology

According to the Form 4 filed with the SEC on August 17, 2026, Troy Edward Wilson, President and CEO of Kura Oncology, Inc., acquired 100,000 shares of the company's common stock. The filing states the transaction was executed in multiple trades at prices ranging from $10.87 to $11.31, with a weighted average purchase price of $11.12. The filing further notes that Wilson "undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."

The purchased shares are held indirectly through the One Fish Two Fish Revocable Trust, bringing the total shares in that trust to 379,194 following the transaction. Separately, the filing discloses 300,000 shares held indirectly through the Lorax Charitable Remainder Unitrust, and 435,456 shares held directly, though no transactions were reported for those two positions in this filing. The Form 4 was signed by Teresa Bair as attorney-in-fact for Troy E. Wilson and dated August 17, 2026.

No derivative securities transactions were reported in Table II of the filing. The filing does not indicate whether the purchase was made under a Rule 10b5-1 trading plan, as that checkbox was not selected on the form.

What Was Disclosed

The filing reports a single open-market purchase of 100,000 shares of Kura Oncology common stock by CEO Troy Wilson on August 17, 2026, at a weighted average price of $11.12, with resulting indirect beneficial ownership of 379,194 shares through a revocable trust.